Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
- PMID: 30044619
- DOI: 10.1021/acs.jmedchem.8b00741
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Abstract
SMA is an inherited disease that leads to loss of motor function and ambulation and a reduced life expectancy. We have been working to develop orally administrated, systemically distributed small molecules to increase levels of functional SMN protein. Compound 2 was the first SMN2 splicing modifier tested in clinical trials in healthy volunteers and SMA patients. It was safe and well tolerated and increased SMN protein levels up to 2-fold in patients. Nevertheless, its development was stopped as a precautionary measure because retinal toxicity was observed in cynomolgus monkeys after chronic daily oral dosing (39 weeks) at exposures in excess of those investigated in patients. Herein, we describe the discovery of 1 (risdiplam, RG7916, RO7034067) that focused on thorough pharmacology, DMPK and safety characterization and optimization. This compound is undergoing pivotal clinical trials and is a promising medicine for the treatment of patients in all ages and stages with SMA.
Similar articles
-
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.Pharmacol Res Perspect. 2018 Nov 29;6(6):e00447. doi: 10.1002/prp2.447. eCollection 2018 Dec. Pharmacol Res Perspect. 2018. PMID: 30519476 Free PMC article.
-
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.Br J Clin Pharmacol. 2019 Jan;85(1):181-193. doi: 10.1111/bcp.13786. Epub 2018 Nov 16. Br J Clin Pharmacol. 2019. PMID: 30302786 Free PMC article. Clinical Trial.
-
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).Expert Opin Investig Drugs. 2022 May;31(5):451-461. doi: 10.1080/13543784.2022.2056836. Epub 2022 Apr 11. Expert Opin Investig Drugs. 2022. PMID: 35316106 Review.
-
Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.Sci Rep. 2020 Oct 15;10(1):17472. doi: 10.1038/s41598-020-74346-9. Sci Rep. 2020. PMID: 33060681 Free PMC article.
-
Risdiplam: First Approval.Drugs. 2020 Nov;80(17):1853-1858. doi: 10.1007/s40265-020-01410-z. Drugs. 2020. PMID: 33044711 Review.
Cited by
-
Mouse models of SMA show divergent patterns of neuronal vulnerability and resilience.Skelet Muscle. 2022 Sep 12;12(1):22. doi: 10.1186/s13395-022-00305-9. Skelet Muscle. 2022. PMID: 36089582 Free PMC article.
-
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023.Molecules. 2023 Dec 21;29(1):68. doi: 10.3390/molecules29010068. Molecules. 2023. PMID: 38202651 Free PMC article. Review.
-
Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.PLoS One. 2024 Mar 1;19(3):e0298609. doi: 10.1371/journal.pone.0298609. eCollection 2024. PLoS One. 2024. PMID: 38427665 Free PMC article.
-
Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects.Nat Rev Genet. 2023 Apr;24(4):251-269. doi: 10.1038/s41576-022-00556-8. Epub 2022 Dec 16. Nat Rev Genet. 2023. PMID: 36526860 Review.
-
Regulation of Survival Motor Neuron Gene Expression by Calcium Signaling.Int J Mol Sci. 2021 Sep 23;22(19):10234. doi: 10.3390/ijms221910234. Int J Mol Sci. 2021. PMID: 34638572 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical